Literature DB >> 7161421

The histogenesis of malignant melanoma in relation to pre-existing pigmented lesions.

V Crucioli, J Stilwell.   

Abstract

One hundred and twenty-nine cases of malignant melanoma seen at Bangour General Hospital over an eleven year period were reviewed clinically and histologically. In 51 patients (39.5%) there was a history of pre-existing pigmented lesion at the site of the melanoma. In 14 cases (10.8%) histology confirmed traces of a benign melanocytic naevus. The relationships between naevus cells and malignant melanocytes are described. The patterns most frequently observed were those of intradermal naevus cells in the deeper part of an invasive melanoma and of a compound naevus undergoing malignant change in its junctional component. From these histological observations a histogenetic sequence of events is postulated. In the 37 patients with a positive history of a preceding pigmented lesion but no histological traces of a naevus, the percentage incidence of Lentigo Maligna (LM) and Superficial Spreading Melanoma (SSM), as compared with the 78 patients with a negative clinical history, was significantly higher than the incidence of nodular melanoma (NM). Although LM and SSM are thought to have separate histogenesis and aetiology, they share an important clinical and histological factor, i.e. in both, the radial growth phase is preceded by a, more or less, prolonged stage of intraepidermal horizontal growth. It is postulated that this pre-existing lesion of atypical melanocytic proliferation rather than a hypothetical benign naevus is in most cases the precursor of an invasive melanoma.

Entities:  

Mesh:

Year:  1982        PMID: 7161421     DOI: 10.1111/j.1600-0560.1982.tb01078.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Malignant melanoma--its precursors and its topography of proliferation. DNA-Feulgen-cytophotometry and mitosis index.

Authors:  P Schmiegelow; R Schroiff; E Breitbart; J Bahnsen; J Lindner; M Jänner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

3.  Melanoma in situ (MIS) adjacent to an invasive nodular melanoma ("SSM/NM") and its metastases--DNA-cytophotometry, mitotic index, and anisokaryosis.

Authors:  P Schmiegelow; T Oppermann; A Nüssgen; R Schroiff; M Jänner; E W Breitbart
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 4.  Melanoma: clinical features and genomic insights.

Authors:  Elena B Hawryluk; Hensin Tsao
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

5.  Morphometric and ultrastructural analyses of melanocytes, nevus cells, and melanoma cells.

Authors:  W Stolz; C Schmoeckel; F Ryckmanns; J Gross; O Braun-Falco
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.

Authors:  Agnessa Gadeliya Goodson; Murray A Cotter; Pamela Cassidy; Mark Wade; Scott R Florell; Tong Liu; Kenneth M Boucher; Douglas Grossman
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

7.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

8.  ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma.

Authors:  Amir Varedi; Hafeez Rahman; Dileep Kumar; Jonathan L Catrow; James E Cox; Tong Liu; Scott R Florell; Kenneth M Boucher; Nwanneka Okwundu; William J Burnett; Matthew W VanBrocklin; Douglas Grossman
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.